

LONDON  
SCHOOL of  
HYGIENE  
& TROPICAL  
MEDICINE



LSHTM Research Online

Alfellani, MA; Stensvold, CR; Vidal-Lapiedra, A; Onuoha, ES; Fagbenro-Beyioku, AF; Clark, CG; (2013) Variable geographic distribution of Blastocystis subtypes and its potential implications. *Acta tropica*, 126. pp. 11-18. ISSN 0001-706X DOI: <https://doi.org/10.1016/j.actatropica.2012.12.011>

Downloaded from: <http://researchonline.lshtm.ac.uk/588991/>

DOI: <https://doi.org/10.1016/j.actatropica.2012.12.011>

**Usage Guidelines:**

Please refer to usage guidelines at <https://researchonline.lshtm.ac.uk/policies.html> or alternatively contact [researchonline@lshtm.ac.uk](mailto:researchonline@lshtm.ac.uk).

Available under license: <http://creativecommons.org/licenses/by-nc-nd/2.5/>

<https://researchonline.lshtm.ac.uk>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

**Title**

Variable geographic distribution of *Blastocystis* subtypes and its potential implications

**Authors**

Mohammed A. Alfellani<sup>a,e</sup>, C. Rune Stensvold<sup>b</sup>, Amparo Vidal-Lapiedra<sup>c</sup>, Emeh Sunday Uche Onuoha<sup>d</sup>, Adetayo F. Fagbenro-Beyioku<sup>d</sup>, C. Graham Clark<sup>a\*</sup>

**Affiliations**

<sup>a</sup>Pathogen Molecular Biology Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK

<sup>b</sup>Department of Microbiology and Infection Control, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark.

<sup>c</sup>Departamento de Biología Celular y Parasitología, Facultad de Farmàcia, Universitat de València. Av. Vicent Andrés Estellés s/n c.p: 46100 Burjassot, Valencia, Spain

<sup>d</sup>Parasitology Unit, Department of Medical Microbiology & Parasitology, College of Medicine, University of Lagos, P.M.B 12003, Nigeria.

<sup>e</sup>Department of Parasitology, Faculty of Medicine, Sebha University, Sebha, Libya

**\*Corresponding author:**

C. Graham Clark, Pathogen Molecular Biology Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK. Tel: +44-20-7927-2351; Fax: +44-20-7636-8739

Email: [graham.clark@lshtm.ac.uk](mailto:graham.clark@lshtm.ac.uk)

1  
2  
3  
4  
5 **Abstract**  
6

7 *Blastocystis* is a common intestinal micro-eukaryote found in both humans and non-human hosts  
8 and known to be genetically very diverse. It has been divided into numerous subtypes (STs), nine  
9 of which have been identified in humans to date. Surveys of ST prevalence have started to  
10 emerge over the past few years but to date no data are available for any African country except  
11 Egypt and Tanzania. In this study, we determined the prevalence of *Blastocystis* STs in  
12 populations from Libya, Liberia and Nigeria, as well as expanding the dataset available for the  
13 UK. A total of 356 *Blastocystis* STs were identified in this study, 271 from the UK, 38 from  
14 Libya, 25 from Liberia and 22 from Nigeria. SSU rRNA gene sequences revealed the presence of  
15 eight of the nine STs known from humans but at varying frequencies between countries. ST1 was  
16 the most common ST in Libya and Nigeria whereas ST3 showed the highest frequency in the  
17 other two countries, as indeed is the case in most populations around the world. ST4 was absent  
18 in Libya and ST2 in Nigeria, while no ST5, ST6, ST8 or ST9 infections were detected in any of  
19 the three African populations. The picture emerging from this and other surveys suggests that  
20 there is significant variation in ST prevalence between populations. Some of the possible reasons  
21 for and implications of this diversity are discussed.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45

46 **Keywords:** *Blastocystis*, diversity, epidemiology  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5 **1. Introduction**  
6

7 *Blastocystis* is a common intestinal parasitic micro-eukaryote with a worldwide distribution and  
8 is often the most frequently detected parasite in epidemiological surveys (Clark et al., in press).  
9  
10 Its prevalence varies from country to country and among various communities within the same  
11 country. Generally, however, the prevalence in developing countries is higher than in developed  
12 countries, which has been linked to standards of hygiene, waste disposal, exposure to animals,  
13 and consumption of contaminated food or water (Tan, 2008), although direct evidence for some  
14 of these is lacking.  
15  
16

17 DNA-based methods have been developed that are able to identify genetic variation between  
18 *Blastocystis* organisms that are morphologically indistinguishable under the microscope.  
19

20 Molecular studies have focused mostly on determining the prevalence of *Blastocystis* subtypes  
21 (STs) in asymptomatic and symptomatic individuals (Böhm-Gloning et al., 1997; Kaneda et al.,  
22 2001; Souppart et al., 2009; Stensvold et al., 2011a; Stensvold et al., 2009; Yan et al., 2006;  
23 Yoshikawa et al., 2004). In spite of recent methodological advances, the molecular epidemiology  
24 of *Blastocystis* infections is still unknown in many parts of the world. Recent studies are starting  
25 to provide more information on the distribution of STs among human populations (Tan, 2008;  
26 Clark et al., in press) but most have been carried out in temperate regions. To date there is some  
27 indication of geographic variation in the prevalence of STs (eg. Forsell et al., 2012a,b) as well as  
28 reports of associations between specific STs and disease, although with conflicting conclusions  
29 (eg. Domínguez-Márquez et al., 2009; Jones et al., 2009; Stensvold et al., 2011a; Tan et al.,  
30 2008).  
31

32 In this study our aim is to investigate the distribution of *Blastocystis* STs from unselected  
33 individuals in North and West Africa, where climates, cultures and ecological conditions are  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2 likely to be quite different from most regions surveyed to date. This will fill a geographic gap in  
3  
4 our knowledge of *Blastocystis* diversity around the world and also provide an insight into  
5  
6 whether such variables influence ST distribution. In addition, we greatly expand the data  
7  
8 available on ST prevalence for the UK.  
9  
10  
11  
12  
13

## 14 **2. Materials and Methods**

### 15 *2.1. Source of specimens*

16  
17 UK samples: A total of 271 new *Blastocystis* isolates from samples submitted for routine ova and  
18  
19 parasite analysis were studied; 136 came from Irritable Bowel Syndrome (IBS) clinics in  
20  
21 England, while the other 135 were submitted by the patient's physician, usually because the  
22  
23 patient was symptomatic but the cause was unknown. Both sample groups were received through  
24  
25 the Diagnostic Parasitology Laboratory of the London School of Hygiene and Tropical  
26  
27 Medicine. The final patient diagnosis is not known and it is likely that some IBS clinic samples  
28  
29 were from patients later diagnosed with non-IBS causes of their symptoms and, equally, some of  
30  
31 the physician-submitted samples were likely from patients with IBS. Ethical approval for work  
32  
33 on the UK samples was obtained (LSHTM reference no.5026).  
34  
35  
36  
37  
38  
39  
40

41  
42 Libya samples: 150 faecal samples submitted for ova and parasite examination by Libyan  
43  
44 patients attending the Sebha Central Medical Laboratory were studied. The samples were  
45  
46 submitted in order for the patient to get a health certificate, join the army, or attend university,  
47  
48 rather than because the patient was symptomatic. 42 (28%) of these samples were positive by  
49  
50 direct smear and 38 of these grew in culture. The Ethics Committee of Sebha University  
51  
52 concluded that no specific approval was needed for the further analysis reported here. Sebha is a  
53  
54 city in southwestern Libya (27°2'0" North, 14°26'0" East) with a population of 130,000. It was  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 historically the capital of the Fezzan region and is now capital of the Sebha District. The weather  
4  
5 is hot and dry in summer and cold and dry in winter.  
6

7  
8 Liberian samples: 43 faecal samples from children aged 6-18 from Bomi, Bong and Margibi  
9  
10 counties, Liberia, were included. These three counties are to the Northwest, Northeast and East  
11  
12 of the capital Monrovia (6°18'48"North 10°48'5"West), respectively. 30 (70%) of the samples  
13  
14 were positive for *Blastocystis* by PCR. Informed consent was obtained from the parents or school  
15  
16 director for analysis of samples from under-age children. Liberia has a hot equatorial climate  
17  
18 with the rainy season between May to October.  
19  
20

21  
22 Nigerian samples: 47 faecal samples were obtained from Nigerian patients (median age 32 y,  
23  
24 inter-quartile range: 24-41 y) attending a clinic in Lagos. The Ethics and Experimentation  
25  
26 Committee of the College of Medicine, University of Lagos PEPFAR/APIN and Lagos  
27  
28 University Teaching Hospital, concluded that no ethical permission was needed for this work. 23  
29  
30 (49%) of the samples were positive for *Blastocystis* by PCR. Lagos is a metropolitan city located  
31  
32 in the southwest region of Nigeria (6°27'11" North, 3°23'45" East). A typical tropical rainforest  
33  
34 climate exists in the city. The population of Lagos is estimated at over 10 million.  
35  
36  
37  
38  
39  
40  
41

## 42 2.2. Sample processing

43  
44 Approximately 50 mg of each Libyan and UK faecal sample was inoculated into Robinson's  
45  
46 medium (Clark and Diamond, 2002) or (in Libya only) a modification of Jones' medium  
47  
48 (Leelayoova et al., 2002) using a Luria agar slant and supplemented with 10% human serum. The  
49  
50 culture was incubated at 37 °C and examined every two days. Positive cultures were passaged  
51  
52 into fresh medium for another 3-4 days, then *Blastocystis* was harvested by centrifugation and  
53  
54 the pellet resuspended in lysis buffer for DNA extraction using the Puregene core kit A (Qiagen,  
55  
56 Crawley, UK) according to the manufacturer's protocol. This rapid DNA extraction prevents the  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 possibility of differential ST growth affecting subsequent analyses in our experience. DNA of  
4  
5 samples from Nigeria and Liberia was extracted directly from faeces using the QIAamp DNA  
6  
7 Stool Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations.  
8  
9

### 10 11 12 2.3. PCR amplification and sequencing 13

14  
15 PCR amplification of partial *Blastocystis* small subunit ribosomal RNA genes (SSU-rDNA) for  
16  
17 subtyping of samples from the UK, Liberia and Libya was performed (at LSHTM) in a 40µl  
18  
19 volume reaction using Biomix (Bioline, London, UK) and the primers BhRDr (5'GAG CTT TTT  
20  
21 AAC TGC AAC AAC G3') and RD5 (5'ATC TGG TTG ATC CTG CCA GTA3') at 2 µM  
22  
23 concentration. These primers amplify a 600 bp region of the SSU-rDNA that contains sufficient  
24  
25 information for unambiguous assignment of STs to samples (Scicluna et al., 2006). The  
26  
27 following amplification profile was used: 30 cycles of denaturation at 94 °C for 30 seconds,  
28  
29 annealing at 59 °C for 30 seconds and extension at 72 °C for 30 seconds. PCR products were  
30  
31 purified using the QiaQuick gel extraction kit (Qiagen, Hilden, Germany) or the GeneJet PCR  
32  
33 Purification kit (Fermentas, Epsom, UK) and sequenced using the BhRDr primer as described  
34  
35 previously (Scicluna et al., 2006).  
36  
37  
38  
39  
40

41  
42 Nigerian samples were screened for *Blastocystis* by PCR (at the SSI) using the primers  
43  
44 b11400ForC and b11710RevC, which amplify a 310 bp SSU-rDNA product, or the primers F1  
45  
46 and BHCRseq3, amplifying a 550 bp product, and Extract-N-Amp PCR ReadyMix (Sigma–  
47  
48 Aldrich Denmark, Brøndby, Denmark). PCR products were sequenced as described previously  
49  
50 (Stensvold et al., 2007; Stensvold et al., 2006).  
51  
52

53  
54 STs were assigned based on the results of BLAST analysis against the databases at NCBI and/or  
55  
56 [www.pubmlst.org/blastocystis](http://www.pubmlst.org/blastocystis). Nucleotide sequences of samples from which unambiguous  
57  
58  
59  
60  
61  
62  
63  
64  
65

barcode sequences were obtained have been submitted to the isolate database at [www.pubmlst.org/blastocystis](http://www.pubmlst.org/blastocystis).

### 3. Results and discussion

#### 3.1. UK samples

The samples from the UK had two distinct origins and could therefore have had distinct ST characteristics: half of the samples were submitted by IBS clinics. The ST profiles of the two sets of samples were compared using the chi-square test. Although there was a clear excess of ST4 in IBS samples, the distribution of STs in the two sample groups did not show any significant difference overall ( $p = 0.18$ ; Table1), so we have combined the two sets of data for geographic comparisons.

The distribution of STs in the UK samples is generally similar to those reported previously in the UK and elsewhere in Europe (Table 2), where ST3 is the most frequently detected ST, followed by ST4, with STs 1 and 2 each having a prevalence of about 10% .

#### 3.2. African samples and comparison with UK samples

In Libya the prevalence of *Blastocystis* has been reported previously to be 26.6% (Alfellani et al., 2007), which is very similar to the prevalence in the current samples (28%). The prevalence of *Blastocystis* in Liberia has not been reported to date and the only report from Nigeria is a prevalence of 2.5% (in Ogun State) using microscopy (Reinthalder et al., 1988).

The only previous reports of ST prevalence in Africa are from three studies conducted in Egypt and a small one in Tanzania (Table 2). Libya, Nigeria, Liberia and Egypt cover a range of distinct climate conditions. Despite this, ST3 was highly prevalent in all countries (ca. 30-60%;



1  
2  
3 Table 3), although ST1 was detected at the highest frequency in both Libya and Nigeria, with  
4  
5 50% and 45.5% respectively. In neither the Nigerian samples nor in two of the studies from  
6  
7 Egypt (Egypt1 and Egypt3; Table 3) was ST2 detected, in contrast to most previous surveys and  
8  
9 the other three locations sampled in this study.

10  
11  
12 Despite ST4 being the second most common ST detected in the UK and being quite common in  
13  
14 both Liberia and Nigeria, in Libya and Egypt it was not detected at all. ST6 and ST7 were both  
15  
16 found in the UK and ST7 in Libya although rarely. However in Egypt these two STs show a high  
17  
18 prevalence in two of the published studies (10-25% for each ST in Hussein et al. (2008) and  
19  
20 Fouad et al. (2011)) despite not being found at all in the other study (Souppart et al, 2010). ST5  
21  
22 and ST8 were not detected in any African country but this is perhaps not surprising as they are  
23  
24 rare in all human surveys (<1%).  
25  
26  
27

28  
29 The UK distribution showed a significant difference from all the African studies except that in  
30  
31 Egypt by Souppart et al. (2010), although for the Liberian study the difference, while still  
32  
33 present, was less striking ( $0.05 > P > 0.01$ ). The Libyan and Liberian distributions showed no  
34  
35 significant difference from the Nigerian or the Egypt2 (Souppart et al., 2010) distributions,  
36  
37 although they differed from each other. It is notable that Souppart et al. (2010) differed from the  
38  
39 other Egyptian studies in using SSU-rDNA sequence-based identification of STs, compared to  
40  
41 the Sequence Tagged Site (STS) PCR-only approach in the other two. Whether this difference in  
42  
43 methodological approach has affected the results of the Egyptian surveys is unclear.  
44  
45  
46  
47  
48  
49  
50

### 51 3.3. Review of *Blastocystis* subtypes in IBS patients

52

53  
54 Although we found no significant difference between the UK samples submitted by IBS clinics  
55  
56 and those submitted from other sources, primarily personal physicians, we feel that some  
57  
58 discussion of ST distribution in IBS patients is worthwhile. There have been three previous  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 studies carried out on the distribution of *Blastocystis* STs in such patients, in Pakistan, Turkey  
4  
5 and Egypt. Since the number of IBS samples in Turkey (Dogruman-Al et al., 2009a) was only  
6  
7 five we have limited the comparison with our IBS clinic sample results to the data from Pakistan  
8  
9 (Yakoob et al., 2010) and Egypt (Fouad et al., 2011) (Table 4).

10  
11 In Pakistan, ST1 is the most common ST detected in IBS samples, whereas ST3 is the most  
12  
13 frequent ST in Egypt and the UK. ST4 is the second most frequently detected in the UK (37.5%)  
14  
15 and is 1.5x more common in IBS compared to other samples (see above). In contrast, ST4 in  
16  
17 Pakistan makes up less than 5% of IBS samples and in Egypt it was not detected at all.

18  
19 The non-IBS ('control') *Blastocystis* STs were also compared from the same studies (Table 5).  
20  
21 This time, in all three countries ST3 was the most common ST. Again, in the UK ST4 was the  
22  
23 second most frequently detected, but in Pakistan ST1 and in Egypt ST6 were the second most  
24  
25 common STs. In Egypt, ST6 and ST7 were both much more common than in either of the other  
26  
27 two countries, although even in Pakistan they were more common than in the UK. It is clear that  
28  
29 no consistent pattern exists between IBS-linked samples and the ST of *Blastocystis* detected  
30  
31 since the distribution observed is very different in each country.  
32  
33  
34  
35  
36  
37  
38  
39  
40

#### 41 *3.4 Aspects of the relative global distribution of Blastocystis subtypes*

42  
43 Information on variation in the distribution of STs between geographic locations is only starting  
44  
45 to emerge and large gaps remain to be filled on the world map. In this study we have partially  
46  
47 filled one gap, in North and West Africa, by presenting data from Libya, Liberia and Nigeria.  
48  
49

50  
51 These data can now be compared to those from other regions of the world.

52  
53 The difference in the relative diversity and prevalence of STs isolated from humans might reflect  
54  
55 different epidemiological and demographic characteristics including climate, geography, cultural  
56  
57 habits, exposure to reservoir hosts, and mode of transmission. The ST distribution in the UK  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 population sampled in the present study was quite similar to that found in previous UK studies  
4  
5 and those from elsewhere in Europe (Table 2). In contrast, ST distributions in the African  
6  
7 countries showed variable similarity to each other and to studies performed elsewhere in the  
8  
9 world.

10  
11 The three studies carried out in Egypt used different techniques to identify *Blastocystis* STs.

12  
13 Hussein et al. (2008) and Fouad et al. (2011) used the STS technique and found similar

14  
15 *Blastocystis* ST frequencies (ST1, ST3, ST6 and ST7) even though samples came from different

16  
17 cities in Egypt (Cairo and Ismailia). In contrast, Souppart et al. (2010), also sampling in Cairo,

18  
19 used sequencing and reported ST distributions quite different from the other two studies (Table

20  
21 3). It is not clear whether the choice of methodology has affected the results in any way, but it

22  
23 suggests that a comparative study is needed using both techniques on the same Egyptian

24  
25 samples. Although Libya has a long border with Egypt and people frequently migrate between

26  
27 the two countries, different *Blastocystis* ST distributions are still observed between the two

28  
29 populations sampled using sequencing methodology ( $p=0.026$ ).

30  
31 ST1 has been suggested by some authors to be linked to zoonotic transmission from farm

32  
33 animals (Noël et al., 2005; Tan, 2008). The finding that this ST was the most common in the

34  
35 Libyan population might suggest that exposure to animal faeces could be a significant source of

36  
37 infection. Many people in Libya keep animals at home, including goats and sheep, or on a family

38  
39 farm, such as cows and camels, and they use them for food and milk. However, there is, in fact, a

40  
41 low prevalence of ST1 in domestic animals surveyed to date in Libya (Alfellani et al., in

42  
43 preparation) so it seems unlikely they are a significant source of infection for humans. In contrast

44  
45 ST5 is very common in Libyan domestic animals but was not detected in any human samples

46  
47 from that country.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 ST2 also shows evidence of some geographic variation in frequency of detection (Figure 1;  
4  
5 Table 2). In Africa, Australia and East Asia it is rare, with a detection rate of 7% or less  
6  
7 compared to over 12% in the other regions with reasonable levels of sampling. Once again,  
8  
9 however, studies using STS appear less likely to detect ST2 than sequence-based surveys in the  
10  
11 same regions (Table 2).  
12  
13

14  
15 ST3 is the most prevalent overall in humans (44.1%; Table 2) and is the most commonly  
16  
17 detected ST in a majority of individual studies. The exceptions are those studies performed in  
18  
19 Libya, Nigeria, Thailand, Brazil, and one study each from Pakistan, Iran, and Turkey, where ST1  
20  
21 was the most common; the other exceptions are the studies from Ireland (ST2), Spain (ST4), one  
22  
23 study from Denmark (ST4) and one study from Nepal (ST7). The study from Spain was  
24  
25 remarkable, since ST3 was not found at all; however, the majority of the patients had acute  
26  
27 diarrhoea, and ST4 was similarly found in more than 70% of *Blastocystis* infected patients with  
28  
29 acute diarrhoea in one Danish study (Stensvold et al., 2011).  
30  
31

32  
33 ST4 is the second most common ST in the UK and is commonly found across Europe (Table 2).  
34  
35 It is not known why ST4 is so common in Europe and much less frequently detected or absent in  
36  
37 the Far East, South America and North Africa (Table 2). Rodents have been identified as a  
38  
39 reservoir host of ST4 (Noël et al., 2005; Noël et al., 2003; Silberman et al., 1996; Yoshikawa et  
40  
41 al., 1998) but exposure to rodent faeces is likely to be almost universal. It is notable that ST4 is  
42  
43 rare in those studies where ST1 is the most commonly identified and that many studies where  
44  
45 ST4 is rare or absent were conducted in countries that are subtropical and/or have mostly Muslim  
46  
47 populations. However, no information on *Blastocystis* STs is available from other North African  
48  
49 countries, many Middle Eastern countries or India, which means that gaps exist in our  
50  
51 knowledge of the distribution of *Blastocystis* STs that might allow us to link studies where ST4  
52  
53 is absent across a large geographical area. It is important to remember that our African ST data  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 are limited in both sample number and geography. Only one location was sampled in Libya and  
4  
5 Nigeria so, for example, we do not know whether the findings from Sebha and Lagos are  
6  
7 representative of the whole of Libya and Nigeria or whether we would obtain different results in  
8  
9 different parts of these countries, as in the three studies from Egypt (Table 3).  
10  
11  
12  
13  
14

### 15 *3.5 Correlation between Blastocystis subtypes and disease*

16  
17 Whether *Blastocystis* has a role in human disease is uncertain because the organism is found  
18  
19 commonly in both symptomatic and asymptomatic individuals (Clark et al., in press). Although  
20  
21 many reports have linked *Blastocystis* to gastrointestinal disorders, the clinical importance of this  
22  
23 organism has not yet been defined. The parasite has been linked with gastrointestinal symptoms  
24  
25 such as watery and mucousy diarrhoea, vomiting, abdominal cramps and bloating. Some  
26  
27 epidemiological studies have also suggested a role in IBS (Stark et al., 2007; Ustun and Turgay,  
28  
29 2006). Since *Blastocystis* infection is more common in IBS patients (Jimenez-Gonzalez et al.,  
30  
31 2012; Stensvold et al., 2009; Yakoob et al., 2004) and because symptoms linked to *Blastocystis*  
32  
33 resemble IBS, the possible role of *Blastocystis* in this syndrome needs to be investigated.  
34  
35  
36  
37  
38

39 We studied the frequency of STs of *Blastocystis* in patient samples submitted from IBS clinics  
40  
41 with samples from other patients in the UK and compared these results with published data from  
42  
43 other countries. No consistent link between ST and IBS could be identified across studies in  
44  
45 three different countries even though in each case a difference was noted between IBS and non-  
46  
47 IBS samples. This does not mean that *Blastocystis* has no importance in IBS, just that any role  
48  
49 appears not to be linked to a specific ST.  
50  
51  
52  
53

54 A difficulty with these studies is the suitability of the control groups used for comparison. In the  
55  
56 UK, the samples were all from a diagnostic laboratory and the vast majority of these will be from  
57  
58 individuals with gastrointestinal symptoms. There was a higher prevalence of ST4 in the samples  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 from IBS clinics in the UK although it did not reach statistical significance. It is interesting that  
4  
5 ST4 has been linked to non-IBS symptomatic infections in two other European studies (in Spain  
6  
7 and Denmark, mentioned above). However, a link between IBS and ST4 is not seen in Pakistan  
8  
9 or Egypt, where ST1 is significantly more common in IBS patients than controls.

10  
11  
12 It was noted earlier that studies in Egypt gave very different results depending on the subtyping  
13  
14 methodology used. It is possible that methodology could also be impacting on the IBS results  
15  
16 since the IBS studies in Egypt and Pakistan used STS typing while that in the UK used  
17  
18 sequencing to assign STs.  
19  
20  
21  
22  
23

#### 24 **4. Conclusion**

25  
26  
27 We have reinforced the emerging picture of substantial geographic variation in *Blastocystis* ST  
28  
29 distribution. The reasons underlying this variation are as yet unclear as in many studies little  
30  
31 demographic information has been gathered that might yield insights. In the future, sample  
32  
33 numbers for new surveys need to be greater than in the three pilot studies reported here, with  
34  
35 sampling in multiple geographically and climatically distinct sites where possible. Ideally, future  
36  
37 studies would also gather information on the individual's occupation and exposure to animals in  
38  
39 order to improve our understanding of the frequently postulated but unproven role of zoonotic  
40  
41 transmission. To eliminate uncertainty over the influence of methodology on ST results we  
42  
43 recommend the use of sequencing for assigning STs, despite this method's inability to identify  
44  
45 STs in mixed infections (Stensvold, in press).  
46  
47  
48  
49  
50  
51  
52  
53

#### 54 **Acknowledgments**

55  
56 We would like to thank the staff of the Diagnostic Parasitology Laboratory, LSHTM, for  
57  
58 providing the UK samples, the Sebha Central Medical Laboratory for providing the Libyan  
59  
60  
61  
62  
63  
64  
65

1  
2 samples, and the brothers of the Order of Saint John of God in Liberia for facilitating that study.  
3  
4  
5 The UK and Libyan work formed part of the PhD thesis of MAA, who was supported by the  
6  
7 Libyan Government. The work was partly funded by the Danish Council for Independent  
8  
9 Research – Medical Sciences (Grant No. 271-09-0251), Danish Agency for Science Technology  
10  
11 and Innovation.  
12  
13  
14  
15

## 16 17 **References**

18  
19 Alfellani, M.A., Khan, A.H., Al-Gazoui, R.M., Zaid, M.K., Al-Ferjani, M.A., 2007. Prevalence  
20  
21 and clinical features of *Blastocystis hominis* infection among patients in Sebha, Libya. Sultan  
22  
23 Qaboos Univ Med J, 7, 35-40.  
24  
25  
26

27  
28  
29 Böhm-Gloning, B., Knobloch, J., Walderich, B., 1997. Five subgroups of *Blastocystis hominis*  
30  
31 from symptomatic and asymptomatic patients revealed by restriction site analysis of PCR-  
32  
33 amplified 16S-like rDNA. Trop Med Int Health 2, 771-778.  
34  
35  
36

37  
38  
39 Clark, C.G., 1997. Extensive genetic diversity in *Blastocystis hominis*. Mol Biochem Parasitol  
40  
41 87, 79-83.  
42  
43  
44

45  
46 Clark, C.G., Diamond, L.S., 2002. Methods for cultivation of luminal parasitic protists of clinical  
47  
48 importance. Clin Microbiol Rev 15, 329-341.  
49  
50  
51

52  
53 Clark, C.G., van der Giezen, M., Alfellani, M.A., Stensvold, C.R. Recent developments in  
54  
55 *Blastocystis* research. Adv Parasitol (in press).  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 Dogruman-Al, F., Dagci, H., Yoshikawa, H., Kurt, O., Demirel, M., 2008. A possible link  
4  
5 between subtype 2 and asymptomatic infections of *Blastocystis hominis*. Parasitol Res 103, 685-  
6  
7 689.  
8  
9

10  
11  
12 Dogruman-Al, F., Kustimur, S., Yoshikawa, H., Tuncer, C., Simsek, Z., Tanyuksel, M., Araz, E.,  
13  
14 Boorum, K., 2009a. *Blastocystis* subtypes in irritable bowel syndrome and inflammatory bowel  
15  
16 disease in Ankara, Turkey. Mem Inst Oswaldo Cruz 104, 724-727.  
17  
18  
19  
20  
21

22 Dogruman-Al, F., Yoshikawa, H., Kustimur, S., Balaban, N., 2009b. PCR-based subtyping of  
23  
24 *Blastocystis* isolates from symptomatic and asymptomatic individuals in a major hospital in  
25  
26 Ankara, Turkey. Parasitol Res 106, 263-268.  
27  
28  
29  
30  
31

32 Domínguez-Márquez, M.V., Guna, R., Muñoz, C., Gómez-Muñoz, M.T., Borrás, R., 2009. High  
33  
34 prevalence of subtype 4 among isolates of *Blastocystis hominis* from symptomatic patients of a  
35  
36 health district of Valencia (Spain). Parasitol Res 105, 949-955.  
37  
38  
39  
40  
41

42 Eroglu, F., Genc, A., Elgun, G., Koltas, I.S., 2009. Identification of *Blastocystis hominis* isolates  
43  
44 from asymptomatic and symptomatic patients by PCR. Parasitol Res 105, 1589-1592.  
45  
46  
47  
48

49 Eroglu, F., Koltas, I.S., 2010. Evaluation of the transmission mode of *B. hominis* by using PCR  
50  
51 method. Parasitol Res 107, 841-845.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65



1  
2  
3 Forsell, J., Granlund, M., Stensvold, C.R., Clark, C.G., Evengård, B., 2012a. Erratum to:  
4  
5 Subtype analysis of *Blastocystis* isolates in Swedish patients. Eur J Clin Microbiol Infect Dis 31,  
6  
7 1697.  
8  
9

10  
11  
12 Forsell, J., Granlund, M., Stensvold, C.R., Clark, C.G., Evengård, B., 2012b. Subtype analysis of  
13  
14 *Blastocystis* isolates in Swedish patients. Eur J Clin Microbiol Infect Dis 31, 1689-1696.  
15  
16  
17  
18

19  
20 Fouad, S.A., Basyoni, M.M., Fahmy, R.A., Kobaisi, M.H., 2011. The pathogenic role of different  
21  
22 *Blastocystis hominis* genotypes isolated from patients with irritable bowel syndrome. Arab J  
23  
24 Gastroenterol 12, 194-200.  
25  
26  
27  
28

29  
30 Hussein, E.M., Hussein, A.M., Eida, M.M., Atwa, M.M., 2008. Pathophysiological variability of  
31  
32 different genotypes of human *Blastocystis hominis* Egyptian isolates in experimentally infected  
33  
34 rats. Parasitol Res 102, 853-860.  
35  
36  
37  
38

39  
40 Jimenez-Gonzalez, D.E., Martinez-Flores, W.A., Reyes-Gordillo, J., Ramirez-Miranda, M.E.,  
41  
42 Arroyo-Escalante, S., Romero-Valdovinos, M., Stark, D., Souza-Saldivar, V., Martinez-  
43  
44 Hernandez, F., Flisser, A., Olivo-Diaz, A., Maravilla, P., 2012. *Blastocystis* infection is  
45  
46 associated with irritable bowel syndrome in a Mexican patient population. Parasitol Res 110,  
47  
48 1269-1275.  
49  
50  
51  
52

53  
54 Jones, M.S., Whipps, C.M., Ganac, R.D., Hudson, N.R., Boorom, K., Boroom, K., 2009.  
55  
56 Association of *Blastocystis* subtype 3 and 1 with patients from an Oregon community presenting  
57  
58 with chronic gastrointestinal illness. Parasitol Res 104, 341-345.  
59  
60  
61  
62

1  
2  
3  
4  
5 Kaneda, Y., Horiki, N., Cheng, X.J., Fujita, Y., Maruyama, M., Tachibana, H., 2001. Ribodemes  
6  
7 of *Blastocystis hominis* isolated in Japan. Am J Trop Med Hyg 65, 393-396.  
8  
9

10  
11  
12 Lee, I.L., Tan, T.C., Tan, P.C., Nanthiney, D.R., Biraj, M.K., Surendra, K.M., Suresh, K.G.,  
13  
14 2012. Predominance of *Blastocystis* sp. subtype 4 in rural communities, Nepal. Parasitol Res  
15  
16 110, 1553-1562.  
17  
18  
19  
20  
21

22 Leelayoova, S., Taamasri, P., Rangsin, R., Naaglor, T., Thathaisong, U., Mungthin, M., 2002. In-  
23  
24 vitro cultivation: a sensitive method for detecting *Blastocystis hominis*. Ann Trop Med Parasitol  
25  
26 96, 803-807.  
27  
28  
29  
30  
31

32 Li, L.H., Zhang, X.P., Lv, S., Zhang, L., Yoshikawa, H., Wu, Z., Steinmann, P., Utzinger, J.,  
33  
34 Tong, X.M., Chen, S.H., Zhou, X.N., 2007a. Cross-sectional surveys and subtype classification  
35  
36 of human *Blastocystis* isolates from four epidemiological settings in China. Parasitol Res 102,  
37  
38 83-90.  
39  
40  
41  
42  
43

44 Li, L.H., Zhou, X.N., Du, Z.W., Wang, X.Z., Wang, L.B., Jiang, J.Y., Yoshikawa, H.,  
45  
46 Steinmann, P., Utzinger, J., Wu, Z., Chen, J.X., Chen, S.H., Zhang, L., 2007b. Molecular  
47  
48 epidemiology of human *Blastocystis* in a village in Yunnan province, China. Parasitol Int 56,  
49  
50 281-286.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2 Malheiros, A.F., Stensvold, C.R., Clark, C.G., Braga, G.B., Shaw, J.J., 2011. Short report:

3  
4  
5 Molecular characterization of *Blastocystis* obtained from members of the indigenous Tapirapé  
6  
7 ethnic group from the Brazilian Amazon region, Brazil. Am J Trop Med Hyg 85, 1050-1053.  
8  
9

10  
11  
12 Meloni, D., Sancier, G., Poirier, P., El Alaoui, H., Chabé, M., Delhaes, L., Dei-Cas, E., Delbac,  
13  
14 F., Luigi Fiori, P., Di Cave, D., Viscogliosi, E., 2011. Molecular subtyping of *Blastocystis* sp.  
15  
16 isolates from symptomatic patients in Italy. Parasitol Res 109, 613-619.  
17  
18  
19  
20  
21

22 Menounos, P.G., Spanakos, G., Tegos, N., Vassalos, C.M., Papadopoulou, C., Vakalis, N.C.,  
23  
24 2008. Direct detection of *Blastocystis* sp. in human faecal samples and subtype assignment using  
25  
26 single strand conformational polymorphism and sequencing. Mol Cell Probes 22, 24-29.  
27  
28  
29  
30  
31

32 Moosavi, A., Haghighi, A., Mojarad, E.N., Zayeri, F., Alebouyeh, M., Khazan, H., Kazemi, B.,  
33  
34 Zali, M.R., 2012. Genetic variability of *Blastocystis* sp. isolated from symptomatic and  
35  
36 asymptomatic individuals in Iran. Parasitol Res 111, 2311-2315.  
37  
38  
39  
40  
41

42 Motazedian, H., Ghasemi, H., Sadjjadi, S.M., 2008. Genomic diversity of *Blastocystis hominis*  
43  
44 from patients in southern Iran. Ann Trop Med Parasitol 102, 85-88.  
45  
46  
47  
48

49 Nagel, R., Cuttall, L., Stensvold, C.R., Mills, P.C., Bielefeldt-Ohmann, H., Traub, R.J., 2012.  
50  
51 *Blastocystis* subtypes in symptomatic and asymptomatic family members and pets and response  
52  
53 to therapy. Intern Med J 42, 1187-1195.  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 Noël, C., Dufernez, F., Gerbod, D., Edgcomb, V.P., Delgado-Viscogliosi, P., Ho, L.C., Singh,  
4  
5 M., Wintjens, R., Sogin, M.L., Capron, M., Pierce, R., Zenner, L., Viscogliosi, E., 2005.

6  
7 Molecular phylogenies of *Blastocystis* isolates from different hosts: implications for genetic  
8  
9 diversity, identification of species, and zoonosis. J Clin Microbiol 43, 348-355.

10  
11  
12  
13  
14 Noël, C., Peyronnet, C., Gerbod, D., Edgcomb, V.P., Delgado-Viscogliosi, P., Sogin, M.L.,  
15  
16 Capron, M., Viscogliosi, E., Zenner, L., 2003. Phylogenetic analysis of *Blastocystis* isolates from  
17  
18 different hosts based on the comparison of small-subunit rRNA gene sequences. Mol Biochem  
19  
20 Parasitol 126, 119-123.

21  
22  
23  
24  
25  
26  
27 Özyurt, M., Kurt, O., Mølbak, K., Nielsen, H.V., Haznedaroglu, T., Stensvold, C.R., 2008.  
28  
29 Molecular epidemiology of *Blastocystis* infections in Turkey. Parasitol Int 57, 300-306.

30  
31  
32  
33  
34 Petrášová, J., Uzlíková, M., Kostka, M., Petrželková, K.J., Huffman, M.A., Modrý, D., 2011.  
35  
36 Diversity and host specificity of *Blastocystis* in syntopic primates on Rubondo Island, Tanzania.  
37  
38 Int J Parasitol 41, 1113-1120.

39  
40  
41  
42  
43 Poirier, P., Wawrzyniak, I., Albert, A., El Alaoui, H., Delbac, F., Livrelli, V., 2011.  
44  
45 Development and evaluation of a real-time PCR assay for detection and quantification of  
46  
47 *Blastocystis* parasites in human stool samples: prospective study of patients with hematological  
48  
49 malignancies. J Clin Microbiol 49, 975-983.

50  
51  
52  
53  
54  
55  
56 Reinthaler, F.F., Mascher, F., Klem, G., Sixl, W., 1988. A survey of gastrointestinal parasites in  
57  
58 Ogun State, southwest Nigeria. Ann Trop Med Parasitol 82, 181-184.

1  
2  
3  
4  
5 Rene, B.A., Stensvold, C.R., Badsberg, J.H., Nielsen, H.V., 2009. Subtype analysis of  
6  
7 *Blastocystis* isolates from *Blastocystis* cyst excreting patients. Am J Trop Med Hyg 80, 588-592.  
8  
9

10  
11  
12 Rivera, W.L., Tan, M.A., 2005. Molecular characterization of *Blastocystis* isolates in the  
13  
14 Philippines by riboprinting. Parasitol Res 96, 253-257.  
15  
16  
17  
18

19  
20 Roberts, T., Stark, D., Harkness, J., Ellis, J., 2012 Subtype distribution of *Blastocystis* isolates  
21  
22 identified in a Sydney population and pathogenic potential of *Blastocystis*. Eur J Clin Microbiol  
23  
24 Infect Dis (in press).  
25  
26  
27  
28

29  
30 Santín, M., Gómez-Muñoz, M.T., Solano-Aguilar, G., Fayer, R., 2011. Development of a new  
31  
32 PCR protocol to detect and subtype *Blastocystis* spp. from humans and animals. Parasitol Res  
33  
34 109, 205-212.  
35  
36  
37  
38

39  
40 Scanlan, P.D., Marchesi, J.R., 2008. Micro-eukaryotic diversity of the human distal gut  
41  
42 microbiota: qualitative assessment using culture-dependent and -independent analysis of faeces.  
43  
44 ISME J 2, 1183-1193.  
45  
46  
47  
48

49  
50 Scicluna, S.M., Tawari, B., Clark, C.G., 2006. DNA barcoding of *Blastocystis*. Protist 157, 77-  
51  
52 85.  
53  
54  
55

56  
57 Silberman, J.D., Sogin, M.L., Leipe, D.D., Clark, C.G., 1996. Human parasite finds taxonomic  
58  
59 home. Nature 380, 398.  
60  
61  
62  
63  
64  
65

1  
2  
3  
4  
5 Souppart, L., Moussa, H., Cian, A., Sancier, G., Poirier, P., El Alaoui, H., Delbac, F., Boorom,  
6  
7 K., Delhaes, L., Dei-Cas, E., Viscogliosi, E., 2010. Subtype analysis of *Blastocystis* isolates from  
8  
9 symptomatic patients in Egypt. *Parasitol Res* 106, 505-511.  
10  
11

12  
13  
14 Souppart, L., Sancier, G., Cian, A., Wawrzyniak, I., Delbac, F., Capron, M., Dei-Cas, E.,  
15  
16 Boorom, K., Delhaes, L., Viscogliosi, E., 2009. Molecular epidemiology of human *Blastocystis*  
17  
18 isolates in France. *Parasitol Res* 105, 413-421.  
19  
20  
21

22  
23  
24 Stark, D., van Hal, S., Marriott, D., Ellis, J., Harkness, J., 2007. Irritable bowel syndrome: a  
25  
26 review on the role of intestinal protozoa and the importance of their detection and diagnosis. *Int J*  
27  
28 *Parasitol* 37, 11-20.  
29  
30  
31

32  
33  
34 Stensvold, C.R., Comparison of sequencing (barcode region) and STS PCR for *Blastocystis*  
35  
36 subtyping. *J Clin Microbiol* (in press).  
37  
38  
39

40  
41 Stensvold, C.R., Arendrup, M.C., Jespersgaard, C., Mølbak, K., Nielsen, H.V., 2007. Detecting  
42  
43 *Blastocystis* using parasitologic and DNA-based methods: a comparative study. *Diagn Microbiol*  
44  
45 *Infect Dis* 59, 303-307.  
46  
47  
48

49  
50  
51 Stensvold, C.R., Christiansen, D.B., Olsen, K.E., Nielsen, H.V., 2011a. *Blastocystis* sp. subtype  
52  
53 4 is common in Danish *Blastocystis*-positive patients presenting with acute diarrhea. *Am J Trop*  
54  
55 *Med Hyg* 84, 883-885.  
56  
57  
58

1  
2  
3 Stensvold, C.R., Lewis, H.C., Hammerum, A.M., Porsbo, L.J., Nielsen, S.S., Olsen, K.E.,  
4  
5 Arendrup, M.C., Nielsen, H.V., Mølbak, K., 2009. *Blastocystis*: unravelling potential risk factors  
6  
7 and clinical significance of a common but neglected parasite. *Epidemiol Infect* 137, 1655-1663.  
8  
9

10  
11  
12 Stensvold, C.R., Nielsen, S.D., Badsberg, J.H., Engberg, J., Friis-Møller, N., Nielsen, S.S.,  
13  
14 Nielsen, H.V., Friis-Møller, A., 2011b. The prevalence and clinical significance of intestinal  
15  
16 parasites in HIV-infected patients in Denmark. *Scand J Infect Dis* 43, 129-135.  
17  
18  
19

20  
21  
22 Stensvold, R., Brillowska-Dabrowska, A., Nielsen, H.V., Arendrup, M.C., 2006. Detection of  
23  
24 *Blastocystis hominis* in unpreserved stool specimens by using polymerase chain reaction. *J*  
25  
26 *Parasitol* 92, 1081-1087.  
27  
28  
29

30  
31  
32 Tan, K.S., 2008. New insights on classification, identification, and clinical relevance of  
33  
34 *Blastocystis* spp. *Clin Microbiol Rev* 21, 639-665.  
35  
36  
37

38  
39 Tan, T.C., Ong, S.C., Suresh, K.G., 2009. Genetic variability of *Blastocystis* sp. isolates obtained  
40  
41 from cancer and HIV/AIDS patients. *Parasitol Res* 105, 1283-1286.  
42  
43  
44

45  
46 Tan, T.C., Suresh, K.G., Smith, H.V., 2008. Phenotypic and genotypic characterisation of  
47  
48 *Blastocystis hominis* isolates implicates subtype 3 as a subtype with pathogenic potential.  
49  
50  
51 *Parasitol Res* 104, 85-93.  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

1  
2  
3 Thathaisong, U., Worapong, J., Mungthin, M., Tan-Ariya, P., Viputtigul, K., Sudatis, A.,  
4  
5 Noonai, A., Leelayoova, S., 2003. *Blastocystis* isolates from a pig and a horse are closely related  
6  
7 to *Blastocystis hominis*. J Clin Microbiol 41, 967-975.  
8  
9

10  
11  
12 Ustun, S., Turgay, N., 2006. [*Blastocystis hominis* and bowel diseases]. Turkiye Parazitoloj Derg  
13  
14 30, 72-76.  
15  
16  
17

18  
19  
20 Wong, K.H., Ng, G.C., Lin, R.T., Yoshikawa, H., Taylor, M.B., Tan, K.S., 2008. Predominance  
21  
22 of subtype 3 among *Blastocystis* isolates from a major hospital in Singapore. Parasitol Res 102,  
23  
24 663-670.  
25  
26  
27

28  
29  
30 Yakoob, J., Jafri, W., Beg, M.A., Abbas, Z., Naz, S., Islam, M., Khan, R., 2010. Irritable bowel  
31  
32 syndrome: is it associated with genotypes of *Blastocystis hominis*. Parasitol Res 106, 1033-1038.  
33  
34  
35

36  
37 Yakoob, J., Jafri, W., Jafri, N., Khan, R., Islam, M., Beg, M.A., Zaman, V., 2004. Irritable bowel  
38  
39 syndrome: in search of an etiology: role of *Blastocystis hominis*. Am J Trop Med Hyg 70, 383-  
40  
41 385.  
42  
43  
44

45  
46  
47 Yan, Y., Su, S., Lai, R., Liao, H., Ye, J., Li, X., Luo, X., Chen, G., 2006. Genetic variability of  
48  
49 *Blastocystis hominis* isolates in China. Parasitol Res 99, 597-601.  
50  
51  
52

53  
54  
55 Yoshikawa, H., Abe, N., Iwasawa, M., Kitano, S., Nagano, I., Wu, Z., Takahashi, Y., 2000.  
56  
57 Genomic analysis of *Blastocystis hominis* strains isolated from two long-term health care  
58  
59 facilities. J Clin Microbiol 38, 1324-1330.  
60  
61  
62



1  
2  
3  
4  
5 Yoshikawa, H., Nagano, I., Wu, Z., Yap, E.H., Singh, M., Takahashi, Y., 1998. Genomic  
6  
7 polymorphism among *Blastocystis hominis* strains and development of subtype-specific  
8  
9 diagnostic primers. Mol Cell Probes 12, 153-159.  
10


11  
12  
13  
14  
15 Yoshikawa, H., Wu, Z., Kimata, I., Iseki, M., Ali, I.K., Hossain, M.B., Zaman, V., Haque, R.,  
16  
17 Takahashi, Y., 2004. Polymerase chain reaction-based genotype classification among human  
18  
19 *Blastocystis hominis* populations isolated from different countries. Parasitol Res 92, 22-29.  
20  
21

22  
23  
24 Yoshikawa, H., Wu, Z., Pandey, K., Pandey, B.D., Sherchand, J.B., Yanagi, T., Kanbara, H.,  
25  
26 2009. Molecular characterization of *Blastocystis* isolates from children and rhesus monkeys in  
27  
28 Kathmandu, Nepal. Vet Parasitol 160, 295-300.  
29  
30

31  
32  
33  
34  
35  
36  
37 Figure legend.  
38

39  
40  
41 Figure 1. Relative distribution of *Blastocystis* STs across various major geographic regions. The  
42  
43 geographic summary data listed in Table 2 are depicted graphically as a percentage of total  
44  
45 samples subtyped for each region.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

Figure 1  
[Click here to download high resolution image](#)



**Table 1**

Host	Subtype								Total
	ST1	ST2	ST3	ST4	ST5	ST6	ST7	ST8	
<b>IBS</b>	14 (10.3 %)	10 (7.4 %)	56 (41.2 %)	51 (37.5 %)	-	1 (0.7 %)	1 (0.7 %)	3 (2.2 %)	136
<b>Unselected</b>	20 (14.8 %)	16 (11.9 %)	58 (42.9 %)	34 (25.2 %)	2 (1.5 %)	-	3 (2.2 %)	2 (1.5 %)	135
<b>Total</b>	34 (12.5%)	26 (9.6%)	114 (42.1%)	85 (31.4%)	2 (0.7%)	1 (0.4%)	4 (1.5%)	5 (1.8%)	271

Table 1. Comparison of *Blastocystis* subtype distribution in IBS clinic- and physician-submitted sample groups in the UK.

Table 2

Country of sample origin	Technique#	No. of subtype observations	Subtype distribution											Reference
			ST1	ST2	ST3	ST4	ST5	ST6	ST7	ST8	ST9	Mixed ST	Unknown	
Brazil	Sequencing	73	33	27	13	—	—	—	—	—	—	7	—	Malheiros et al., 2011
Colombia	Sequencing	13	5	4	4	—	—	—	—	—	—	1	—	Santin et al., 2011
USA	Sequencing	7	1	—	6	—	—	—	—	—	—	—	—	Jones et al., 2009
<b>AMERICAS TOTAL</b>		<b>93</b>	<b>39</b>	<b>31</b>	<b>23</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>8</b>	<b>0</b>	
Denmark	Sequencing	29	1	6	15	7	—	—	—	—	—	—	—	Stensvold et al., 2006
Denmark	Sequencing	28	5	9	13	1	—	—	—	—	—	—	—	Stensvold et al., 2007
Denmark	Sequencing	92	20	15	39	16	—	1	—	1	—	7	—	Rene et al., 2009
Denmark	Sequencing	143	31	39	42	24	—	—	6	—	1	26	—	Stensvold et al., 2009
Denmark	Sequencing	25	1	4	1	19	—	—	—	—	—	—	—	Stensvold et al., 2011a
Denmark	Sequencing	24	11	—	13	—	—	—	—	—	—	2	—	Stensvold et al., 2011b
France	Sequencing	43	11	4	23	4	—	—	1	—	—	3	—	Souppart et al., 2009
France	Sequencing	27	1	1	4	17	—	1	3	—	—	—	—	Poirier et al., 2011
Germany	RFLP	171	40	1	118	12	—	—	—	—	—	8	—	Böhm-Gloning et al., 1997
Germany	STS	12	3	2	5	2	—	—	—	—	—	—	—	Yoshikawa et al., 2004
Greece	SSCP	45	9	6	27	1	—	1	1	—	—	—	—	Menounos et al., 2008
Ireland	Sequencing	14	1	6	4	3	—	—	—	—	—	—	—	Scanlan and Marchesi, 2008
Italy	Sequencing	34	3	7	16	6	—	—	1	1	—	4	—	Meloni et al., 2011
Spain	RFLP	51	1	2	—	48	—	—	—	—	—	—	—	Dominguez-Márquez et al., 2009
Sweden	Sequencing	63	10	9	30	13	—	—	1	—	—	—	—	Forsell et al., 2012a&b
UK	RFLP	29	2	1	22	4	—	—	—	—	—	—	—	Clark, 1997
UK	Sequencing	48	2	8	20	16	—	—	1	1	—	1	—	Scicluna et al., 2006
UK	Sequencing	271	34	26	114	85	2	1	4	5	—	—	—	Present study
<b>EUROPE TOTAL</b>		<b>1149</b>	<b>186</b>	<b>146</b>	<b>506</b>	<b>278</b>	<b>2</b>	<b>4</b>	<b>18</b>	<b>8</b>	<b>1</b>	<b>51</b>	<b>0</b>	
Egypt	STS	110	15	—	49	—	—	33	13	—	—	10	—	Fouad et al., 2011
Egypt	STS	44	8	—	24	—	—	8	4	—	—	—	—	Hussein et al., 2008
Egypt	Sequencing	21	4	4	13	—	—	—	—	—	—	1	—	Souppart et al., 2010
Liberia	Sequencing	25	7	7	8	3	—	—	—	—	—	5	—	Present study
Libya	Sequencing	38	19	3	15	—	—	—	1	—	—	—	—	Present study
Nigeria	Sequencing	22	10	—	9	3	—	—	—	—	—	1	—	Present study
Tanzania	Sequencing	6	1	3	2	—	—	—	—	—	—	—	—	Petrášová et al., 2011
<b>AFRICA TOTAL</b>		<b>266</b>	<b>64</b>	<b>17</b>	<b>120</b>	<b>6</b>	<b>0</b>	<b>41</b>	<b>18</b>	<b>0</b>	<b>0</b>	<b>17</b>	<b>0</b>	
Bangladesh	STS	26	2	—	24	—	—	—	—	—	—	—	—	Yoshikawa et al., 2004
Iran	RFLP	40	20	4	16	—	—	—	—	—	—	—	5	Motazedian et al., 2008
Iran	STS	141	48	33	53	—	—	—	7	—	—	33	—	Moosavi et al., 2012
Nepal	STS	20	4	4	12	—	—	—	—	—	—	—	—	Yoshikawa et al., 2009
Nepal	STS	101	40	—	—	—	—	8	53	—	—	41	8	Lee et al., 2012
Pakistan	STS	10	2	—	7	—	—	1	—	—	—	—	—	Yoshikawa et al., 2004
Pakistan	STS	177	87	10	49	8	7	6	10	—	—	—	2	Yakoob et al., 2010
Turkey	Sequencing	87	8	12	66	1	—	—	—	—	—	—	—	Özyurt et al., 2008
Turkey	STS	96	19	22	55	—	—	—	—	—	—	4	—	Dogruman-AI et al., 2008
Turkey	STS	32	20	3	9	—	—	—	—	—	—	—	—	Eroglu et al., 2009
Turkey	STS	38	3	13	22	—	—	—	—	—	—	3	—	Dogruman-AI et al., 2009a
Turkey	STS	75	19	11	45	—	—	—	—	—	—	9	—	Dogruman-AI et al., 2009b
Turkey	STS	25	9	6	10	—	—	—	—	—	—	—	—	Eroglu and Koltas, 2010
<b>CENTRAL ASIA TOTAL</b>		<b>868</b>	<b>281</b>	<b>118</b>	<b>368</b>	<b>9</b>	<b>7</b>	<b>15</b>	<b>70</b>	<b>0</b>	<b>0</b>	<b>90</b>	<b>15</b>	
China	STS	38	17	—	19	—	—	—	2	—	—	5	1	Yan et al., 2006
China	STS	194	56	11	125	1	—	1	—	—	—	10	8	Li et al., 2007a
China	STS	76	18	1	56	1	—	—	—	—	—	2	3	Li et al., 2007b
Japan	STS	32	1	—	30	—	—	1	—	—	—	—	—	Yoshikawa et al., 2000
Japan	RFLP	61	11	13	30	7	—	—	—	—	—	—	3	Kaneda et al., 2001
Japan	STS	50	4	—	26	2	—	11	5	—	2	—	—	Yoshikawa et al., 2004
Malaysia	STS	20	9	1	10	—	—	—	—	—	—	—	—	Tan et al., 2008
Malaysia	STS	38	5	—	20	—	—	11	2	—	—	—	2	Tan et al., 2009
Philippines	RFLP	10	10	—	—	—	—	—	—	—	—	—	2	Rivera and Tan, 2005
Singapore	RFLP	9	2	—	7	—	—	—	—	—	—	—	—	Wong et al., 2008
Thailand	RFLP	159	144	—	13	—	—	—	2	—	—	6	—	Thathaisong et al., 2003
Thailand	STS	5	2	—	2	—	—	1	—	—	—	1	—	Yoshikawa et al., 2004
<b>E &amp; SE-ASIA TOTAL</b>		<b>692</b>	<b>279</b>	<b>26</b>	<b>338</b>	<b>11</b>	<b>0</b>	<b>25</b>	<b>11</b>	<b>0</b>	<b>2</b>	<b>24</b>	<b>19</b>	
Australia	Sequencing	12	5	—	4	2	—	1	—	—	—	1	—	Nagel et al., 2012
Australia	Sequencing	91	28	5	40	12	—	3	1	2	—	—	—	Roberts et al., 2012
<b>AUSTRALIA TOTAL</b>		<b>103</b>	<b>33</b>	<b>5</b>	<b>44</b>	<b>14</b>	<b>0</b>	<b>4</b>	<b>1</b>	<b>2</b>	<b>0</b>	<b>1</b>	<b>0</b>	
<b>EARTH</b>	<b>Total</b>	<b>3171</b>	<b>882</b>	<b>343</b>	<b>1399</b>	<b>318</b>	<b>9</b>	<b>89</b>	<b>118</b>	<b>10</b>	<b>3</b>	<b>191</b>	<b>34</b>	

Table 2. Subtype distribution by country of sample origin.

# STS= Sequence-tagged site; RFLP=Restriction fragment length polymorphism; SSCP=Single strand conformation polymorphism

Table 3

Country	Subtype									$\chi^2$ and Fisher's Exact Test results						Reference
	ST1	ST2	ST3	ST4	ST5	ST6	ST7	ST8		UK	Libya	Liberia	Nigeria	Egypt1	Egypt2	
UK	34 (12.5%)	26 (9.6%)	114 (42.1%)	85 (31.4%)	2 (0.7%)	1 (0.4%)	4 (1.5%)	5 (1.8%)	271							Present study
Libya	19 (50%)	3 (7.9%)	15 (39.5%)	-	-	-	1 (2.6%)	-	38	P= <0.0001						Present study
Liberia	7 (28.0%)	7 (28.0%)	8 (32.0%)	3 (12.0%)	-	-	-	-	25	P= 0.022	P= 0.026					Present study
Nigeria	10 (45.5%)	-	9 (40.9%)	3 (13.6%)	-	-	-	-	22	P=0.005	P= 0.140	P= 0.059				Present study
Egypt 1	8 (18.2%)	-	24 (54.5%)	-	-	8 (18.2%)	4 (9.1%)	-	44	P= <0.0001	P= <0.001	P= <0.0001	P= 0.002			Hussein et al., 2008
Egypt 2	3 (15.8%)	4 (20.1%)	12 (63.2%)	-	-	-	-	-	19	P= 0.140	P= 0.026	P= 0.139	P= 0.012	P= 0.005		Souppart et al., 2010
Egypt 3	15 (16.7%)	-	39 (43.3%)	-	-	23 (25.6%)	13 (14.4%)	-	90	P= <0.0001	P= <0.0001	P= <0.0001	P= <0.0001	P= 0.534	P= <0.0001	Fouad et al., 2011
<b>Total</b>	<b>96</b>	<b>40</b>	<b>221</b>	<b>91</b>	<b>2</b>	<b>32</b>	<b>22</b>	<b>5</b>	<b>509</b>							

Table 3. Comparison of *Blastocystis* subtype distribution in some African countries and the UK. The Tanzanian study (Petrášová et al., 2011) was not included due to small numbers. The subtype distributions were compared using the  $\chi^2$  or Fisher's Exact Test as appropriate.

Table 4

Country	Subtype										Total	Reference
	ST1	ST2	ST3	ST4	ST5	ST6	ST7	ST8	Mixed ST	Unidentified ST		
Pakistan	75 (61%)	6 (4.9%)	23 (18.7%)	6 (4.9%)	3 (2.4%)	3 (2.4%)	5 (4.1%)	-	-	2 (1.6%)	123	Yakoob et al., 2010
Egypt	15 (29.4%)	-	22 (43.1%)	-	-	8 (15.7%)	-	-	6 (11.8%)	-	51	Fouad et al., 2011
UK	14 (10.3%)	10 (7.4%)	56 (41.2%)	51 (37.5%)	-	1 (0.7%)	1 (0.7%)	3 (2.2%)	-	-	136	Present study
Total	104	16	101	57	3	12	6	3	6	2	310	

Table 4. Distribution of *Blastocystis* subtypes in IBS clinic samples from different countries.

Table 5

Country	Subtype										Total	Reference
	ST1	ST2	ST3	ST4	ST5	ST6	ST7	ST8	Mixed ST	Unidentified ST		
<b>Pakistan</b>	12 (21.4%)	4 (7.1%)	26 (46.4%)	2 (3.6%)	4 (7.1%)	3 (5.4%)	5 (8.9%)	–	–	–	56	Yakoob et al., 2010
<b>Egypt</b>	–	–	17 (34.7%)	–	–	15 (30.6%)	13 (26.5%)	–	4 (8.2%)	–	49	Fouad et al., 2011
<b>UK</b>	20 (14.8%)	16 (11.9%)	58 (42.9%)	34 (25.2%)	2 (1.5%)	–	3 (2.2%)	2 (1.5%)	–	–	135	Present study
<b>Total</b>	<b>32</b>	<b>20</b>	<b>101</b>	<b>36</b>	<b>6</b>	<b>18</b>	<b>21</b>	<b>2</b>	<b>4</b>	<b>–</b>	<b>240</b>	

Table 5. Distribution of *Blastocystis* subtypes in control groups from IBS studies in different countries.